[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-378866-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-378866-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-winning-new-combination-toward-clinical-application-in-oncology","A Winning New Combination - Toward Clinical Application in Oncology","","Immunotherapy draws major attention in oncology, driven by the clinical success of CTLA-4 and PD-1 inhibitors across melanoma, lung cancer, head and neck cancer, renal cell carcinoma, and Hodgkin’s lymphoma. Understanding tumor–microenvironment interactions and immune-system dynamics guides oncology research and supports innovative strategies. The article reviews the history, key breakthroughs, and future prospects of three gene-therapy modalities—immunotherapy, oncolytic virotherapy, and gene transfer—covering mechanisms of resistance and FDA-authorized combination drugs, including ACT, vaccines, cytokines, innate immune modifiers, and related agents.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-winning-new-combination-toward-clinical-application-in-oncology/378866/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-winning-new-combination-toward-clinical-application-in-oncology/378866.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What key immune targets underlie modern cancer immunotherapy in this article?","Question",{"text":63,"@type":64},"The review highlights CTLA-4 and PD-1 inhibitors as central immunotherapy approaches, noting their clinical activity across multiple tumor types.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which gene-therapy related treatment modalities does the article discuss?",{"text":68,"@type":64},"It explains three modalities: immunotherapy, oncolytic virotherapy, and gene transfer, and links them to gene therapy innovations.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is combination treatment important according to the article?",{"text":72,"@type":64},"It argues that improving immunotherapy effectiveness requires using anti-tumor immune activity at multiple points, achieved through combining different techniques and therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},378866,1790626310,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","A Winning New Combination? Toward Clinical Application in Oncology  \nQuratulain Maqsood 1, Aleena Sumrin 1 􀀁, Maryam Iqbal1, Nazim Hussain 1 􀀁, Muhammada Mahnoor2, Muhammad Zafar Saleem 1 􀀁, and Rukhsana Perveen1  \nCancer Control Volume 30: 1–22  \n© The Author(s) 2023  \nArticle reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10732748231175240](DOI: 10.1177/10732748231175240)[ ](DOI: 10.1177/10732748231175240)[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nAbstract  \nImmunotherapy has substantial attention in oncology due to the success of CTLA-4 and PD-1 inhibitors in the treatment of melanoma, lung cancer, head and neck cancer, renal cell carcinoma, and Hodgkin’s lymphoma. A deeper understanding of interaction of tumor with its environment and the immune system provides best guide for oncology research. Recent studies in oncology have explained how a tumor alters antigen presentation, avoids detection, and activation of the host immune system to live and develop. Understanding the connections between the tumor and the immune system has resulted in several innovative therapy options. The extensive field of gene therapy has provided a number of cutting-edge medicines that are expected to play an important role in lowering cancer-related mortality. This article explains the history, important breakthroughs, and future prospects for three separate gene therapy treatment modalities: immunotherapy, oncolytic virotherapy, and gene transfer. Immunotherapies have completely changed how cancer is treated, especially for individuals whose condition was previously thought to be incurable. Examples include ACT (adoptive cell therapy) and ICB (immune checkpoint blockade). This review article will discuss the relationship between the immune response to cancer and the mechanisms of immunotherapy resistance. It will cover combination drugs authorized by the US Food and Drug Administration and provide a thorough overview of how these drugs are doing clinically right now. Cytokines, vaccines, and other soluble immunoregulatory agents, innate immune modifiers, ACT, virotherapy, and other treatment modalities will all be covered in detail.  \nKeywords  \noncology, immunotherapy, gene therapy, cancer cell, viral vector  \nReceived December 1, 2022. Received revised March 4, 2023. Accepted for publication April 17, 2023.  \nIntroduction  \nCancer immunotherapy has replaced traditional cancer treatments. These medicinal agents have shown clinical activity as monotherapies in a variety of tumors.1 Further advancements in the efficacy of immunotherapies against cancer demand the use of the anti-tumor immune action at various points that are achieved by the combination of different techniques.2 The present landscape of cancer immunotherapy will be discussed in this review and selection of dose and practice techniques, clinical pharmacotherapeutics, combinations in clinical development and regulatory issues will also be discussed.3 Immunotherapy has revolutionized oncology that how different tumors are treated over the last 5 years by  \nutilizing the immune system to target tumors, primarily by reducing the protein of programmed cell death and the protein associated with cytotoxic T lymphocytes (CTLA-4) .4 This methodology is functional and efficient in head and neck  \n1 Centre for Applied Molecular Biology, University of the Punjab Quaid-iAzam Campus, Lahore, Pakistan  \n2Department of Rehabilitation Sciences, Akhtar Saeed Medical & Dental College, Lahore, Pakistan  \nCorresponding Author:  \nNazim Hussain, Centre for Applied Molecular Biology, University of the Punjab Quaid-i-Azam Campus, CAMB, pu LHR, Lahore 54000, Pakistan.  \nEmail: [seithy1223@gmail.com](seithy1223@gmail.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://crea","cbCaitBnxgCyx4Cs","https://ap.wps.com/l/cbCaitBnxgCyx4Cs","pdf",1193308,22,"English","# Abstract\n# Introduction\n## Cancer immunotherapy and clinical development","[{\"question\":\"What key immune targets underlie modern cancer immunotherapy in this article?\",\"answer\":\"The review highlights CTLA-4 and PD-1 inhibitors as central immunotherapy approaches, noting their clinical activity across multiple tumor types.\"},{\"question\":\"Which gene-therapy related treatment modalities does the article discuss?\",\"answer\":\"It explains three modalities: immunotherapy, oncolytic virotherapy, and gene transfer, and links them to gene therapy innovations.\"},{\"question\":\"Why is combination treatment important according to the article?\",\"answer\":\"It argues that improving immunotherapy effectiveness requires using anti-tumor immune activity at multiple points, achieved through combining different techniques and therapies.\"}]","A Winning New Combination - Toward Clinical Application in Oncology | PDF",1790232927,55]